ALKERMES PLC. (ALKS)
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
📈 **POSITIVE** • High confidence analysis (83%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business